About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

MediciNova,Inc.(4875) Summary

4875
TSE Standard
MediciNova,Inc.
217
JPY
0
(0.00%)
May 1, 3:30 pm JST
1.50
USD
May 1, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
Yield
ー%
Margin Trading Ratio
Stock Price
May 1, 2025
Opening May 1, 9:00 am
217 JPY 1.51 USD
Previous Close Apr 30
217 JPY 1.52 USD
High May 1, 9:13 am
223 JPY 1.56 USD
Low May 1, 1:24 pm
213 JPY 1.47 USD
Volume
81,100
Trading Value
0.02B JPY 0.12M USD
VWAP
217.94 JPY 1.51 USD
Minimum Trading Value
21,700 JPY 150 USD
Market Cap
0.01T JPY 0.07B USD
Number of Trades
108
Liquidity & Number of Trades
As of May 1, 2025
Liquidity
Mid
1-Year Average
302
1-Year High Sep 4, 2024
4,635
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 25, 2025 0 161,900
Apr 18, 2025 0 161,500
Apr 11, 2025 0 165,400
Apr 4, 2025 0 201,200
Mar 28, 2025 0 202,900
Company Profile
MediciNova, Inc. is a US-based pharmaceutical development venture focusing on treatments for conditions such as acute asthma attacks.
Sector
Pharmaceuticals
MediciNova, Inc. is a pharmaceutical development company headquartered in the United States, specializing in the development of novel therapeutics for serious diseases. Its lead development product, MN-166 (ibudilast), is being developed for indications including ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence, alcohol use disorder, and Long-COVID. MN-001 (tipelukast) is being developed for non-alcoholic fatty liver disease and idiopathic pulmonary fibrosis. Additionally, a treatment for phenylketonuria is included in the development pipeline. The company has received Fast Track and Orphan Drug designations from the US FDA for several of its development products, indicating a promising development pipeline.